A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival.
According to the Centers for Disease Control and Prevention, in 2012 (the most recent year for which numbers are available) 177,489 men in the United States were diagnosed with prostate cancer, and 27,244 men in the U.S. died from the disease.
Andrea B. Apolo, MD, chief of the Bladder Cancer Section, Center for Cancer Research, at the National Cancer Institute in Bethesda, Md., said, "To our knowledge, this is the first report of follow-up NaF scans of prostate cancer patients over a one-year period correlated with survival. The findings in this study provide support for the use of NaF-PET/CT in clinical practice in patients with advanced prostate cancer."
Sixty prostate cancer patients, including 30 with and 30 without known bone metastases by conventional imaging, underwent NaF-PET/CT at baseline, 6, and 12 months. Positive lesions were verified on follow-up scans. Changes in standardized uptake values (SUV) and lesion number were correlated with prostate-specific antigen (PSA) change, clinical impression, and overall survival. Also, greater change in SUV at 6 and 12 months correlated with greater change in PSA.
In an exploratory analysis, paired Tc-99m-MDP bone scans (TcBS) were available in 35 patients at baseline, 19 at 6 months, and 14 at 12 months. Malignant lesions on NaF-PET/CT were classified on TcBS as malignant only 65 percent of the time; 25 percent were indeterminate; and 10 percent were negative. In addition, 65 percent of paired scans showed more lesions on NaF-PET/CT than on TcBS.
The study shows that NaF-PET/CT detects more bone metastases earlier than TcBS and enhances detection of new bone disease in high-risk patients.
Apolo stated, "Our study suggests that NaF-PET/CT may be a useful imaging modality in the diagnosis, prognosis and follow-up of prostate cancer patients at high risk for bone metastasis. It provides a strong rational to further the clinical development of NaF-PET/CT as a bone imaging tool in prostate cancer and other malignancies.
The above post is reprinted from materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.
Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.
Primary Resource:
Apolo, A. B., Lindenberg, L., Shih, J. H., Mena, E., Kim, J. W., Park, J. C., ... & Parnes, H. L. (2016). Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.Journal of Nuclear Medicine, 57(6), 886-892.
and connect with fellow professionals
At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.
0 Comments
Please log in to post a comment.